Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Q: The release does not mention cost or whether it’s covered by private insurance or Medicare, and in this case, it’s a pretty big omission. This may be an enormously expensive treatment for patients — and it’s why we have a cost criterion in our reviews. The hopeful psoriasis patient who sees this release without a cost discussion might already have their hand on the phone to call their dermatologist. Here’s a very rough estimate of what that patient might face in terms of cost: Based on a conservative wholesale price of roughly $4,000 per 80 mg injection and following the recommendation (found on the package insert) of two injections every two weeks for 12 weeks, followed by monthly injections, we calculated $48,000 for the first 12 weeks plus $36,000 for the following 9 months or $84,000 total. The release stated that by week 12, “76.4 to 81.8 percent of patients had their psoriasis classified as “clear” or “minimal” compared to 3.2% of patients on the placebo. By the 60th week, 68.7 to 78.3 percent of patients had maintained their improvement.” We also wanted more detail on the measured strength of the response for each patient. For example, what constitutes “minimal”? The release adequately addresses harms and notes that long-term side effects are unknown with this sentence: “Adverse events associated with ixekizumab included slightly higher rates of neutropenia (low white blood cell count), yeast infection and inflammatory bowel disease compared to the placebo. The safety of therapy longer than 60 weeks will need to be monitored in the future.” The release clearly and thoroughly describes the three phase 3 international trials at 21 sites, that they enrolled a large number of patients, and that they were randomized and controlled. There was no disease mongering. The release describes what psoriasis is and its prevalence, and explains that these trials were for moderate to severe psoriasis which covers at least 10 percent of the body. The release is very transparent in stating that the drug manufacturer paid for the research and that the lead researcher is a paid consultant to Eli Lilly. The release did not compare the many different ways that patients treat psoriasis, some with topical agents and some with oral steroids or other medications. The release states that the drug has been approved by the FDA following the completion of the trials. This is a strong indication that the drug is or soon will be available. The release should have noted that the drug is already being marketed under the brand name Taltz. The release makes an understated claim to novelty with this quote from the lead researcher: “Ten years ago, we thought complete clearance of this disease was impossible. It wasn’t something we would even try to do. Now with this drug, we’re obtaining response levels higher than ever seen before.” There was no unjustifiable language in the release.

A: New drug clears psoriasis in clinical trials
****
Q: "With an increasing number of coronavirus cases across the country, President Donald Trump pointed to a metric that reflects more favorably on his administration’s pandemic response. On June 23, Trump tweeted, ""Cases up only because of our big number testing. Mortality rate way down!!!"" Cases up only because of our big number testing. Mortality rate way down!!! https://t.co/bKFmgOLEGZ His argument that tests are the only reason for rising cases is not accurate. But on the trend for mortality, Trump has a point. Epidemiologists told PolitiFact that due to wide variations in testing patterns, the data doesn’t offer a clear look at how likely someone is to die from the virus if they are infected with it. Gaps in testing leave too many undiagnosed cases to reliably determine a person’s likelihood of dying from the coronavirus, much less whether the likelihood of dying has risen or fallen over time. Instead, researchers say, the most solid metric for assessing Trump’s statement is the number of new coronavirus deaths reported per day. The number of daily deaths from coronavirus has been falling consistently since peaking in late April. In fact, even as infections have risen since early June, deaths have not. (The orange line in the following chart shows the seven-day rolling average of coronavirus deaths, which smooths out data variations.) At the peak in late April, more than 2,000 were dying from coronavirus on a typical day. In late June, it’s less than 600. That’s still a large number of deaths every day. All told, roughly 115,000 have died from COVID-19 to date. The White House told PolitiFact that the per-capita number of deaths in the United States is also lower than it is in several advanced industrialized countries in Europe that were hard hit by the virus. According to Johns Hopkins University, the number of coronavirus deaths per 100,000 population is about 37 for the United States, compared with 65 in the United Kingdom, 61 in Spain, and 57 in Italy. But other European countries have lower death rates for COVID-19 than the United States does, including the Netherlands, Ireland, Germany, Switzerland and Denmark. So why are deaths falling? There may be several reasons, and for now, they’re somewhat speculative. One possibility is that the initial wave of infections disproportionately reached more patients with weaker immune systems, including those in nursing homes, or more vulnerable Americans who hadn’t yet taken up effective social distancing. By contrast, more recent waves of infections may be reaching younger and healthier people who are better able to survive an infection. Another possibility is that we’re ""getting better at treatment and keeping people alive,"" said Tara Smith, an epidemiologist at Kent State University’s College of Public Health. Still, epidemiologists caution that deaths are a lagging indicator. The disease often takes two to three weeks to run its course, meaning that one day’s crop of new infections tends to drive the deaths that occur two to three weeks later. ""We might not expect an increase in the death rate until approximately 21 days from when we started to see an increase in cases,"" said Brooke Nichols, an infectious disease modeler at the Boston University School of Public Health. So far, the age breakdown for deaths has been fairly consistent — people older than 65 accounted for 81% of coronavirus deaths at the mortality peak in mid-April, and that age group still accounted for 82% of in mid-July, a time when the total number of deaths had fallen significantly, according to the Centers for Disease Control and Prevention. Since we’re about two weeks into the national rise in infections, scientists will be watching to see if deaths start increasing a week from now. Trump said that mortality from coronavirus is ""way down."" This is one of the few coronavirus measurements that Trump can point to with optimism. The number of deaths has remained substantial, at a bit below 600 per day by mid-to-late June, but that’s more than two-thirds lower than the peak of about 2,000 daily deaths in late April. The number of coronavirus deaths per day has continued to fall in June even as the number of cases has risen. Trump’s statement is accurate for now, though it’s too soon to know whether the recent rise in new cases will produce an uptick in deaths by early July."

A: As of June 23, the COVID-19 death rate is “way down.”
****
Q: The increase in deaths was the largest since the outbreak surfaced 10 days ago in the wealthy northern regions of Lombardy and Veneto. Lombardy, around Italy’s financial capital Milan, is by far with hardest hit, with 38 casualties. The virus has since spread south but the vast majority of cases remain centered on the original hotspots, with the addition of Emilia Romagna, another affluent region which borders on both Lombardy and Veneto and now has more cases than Veneto. In total, 2,036 people have tested positive in Italy, up from 1,694 on Sunday. Of these, 149 have recovered, the civil protection agency said. “What is comforting is that 50% of the 258 people who tested positive (in the last 24 hours) have no symptoms or are being looked after at home,” Angelo Borrelli, head of the agency, told reporters. In total, Italy has tested 23,345 people for the disease. The Lombardy regional government urged people over the age of 65 to remain at home, as data showed they were by far the most vulnerable to the highly contagious illness. “All those who have died (in Lombardy) are people over 65 with underlying health conditions, especially cardiovascular problems,” said Giulio Gallera, the region’s councillor responsible for welfare policy. In a worrying development, a policeman and a fireman based in Rome have also tested positive, authorities said, raising the risk of the virus spreading in the Italian capital. Cases in Rome, Italy’s largest city with 3 million people, had previously been limited to a Chinese couple on holiday and an Italian repatriated from the Chinese city of Wuhan - where the outbreak originated late last year - on a special flight and hospitalized. All three recovered. On Monday the Spallanzani infectious diseases hospital where the policeman was staying announced that his wife, two children and sister-in-law were also infected. The school attended by his son, in the nearby town of Pomezia, was closed and lessons were suspended in the university faculty at Rome’s main Sapienza university, attended by his other son. The coronavirus is taking a heavy toll on Italy’s economy, which was already teetering on the verge of recession before the outbreak, with sectors from manufacturing to tourism hit by a plunge in orders. Several international airlines including Lufthansa Delta Airlines and countries such as the Czech Republic have reduced or suspended flights to Italian cities. Milan cathedral reopened to the public on Monday but schools and universities remain closed and many companies told staff to work from home. The top of the UniCredit  skyscraper in Milan was lit in red, white and green, the colors of the Italian flag, in a sign of solidarity with people hit by the virus. National statistics bureau ISTAT reported on Monday that the 2019 budget deficit came in at 1.6% of national output, the smallest fiscal gap for 12 years. The much-lower-than-expected reading potentially gives the coalition of the anti-establishment 5-Star Movement and the center-left Democratic Party more leeway to spend and borrow this year - good news with coronavirus costs soaring. Economy Minister Roberto Gualtieri announced on Sunday the cabinet would this week approve 3.6 billion euros ($3.5 billion) of measures to help companies. An aid package worth 900 million euros was unveiled on Friday for the worst-impacted zones.

A:
Italy coronavirus deaths jump to 52, cases climb above 2,000.
****